28165762|t|Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial
28165762|a|This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the α2 agonist guanfacine extended-release (GXR) in children and adolescents with generalized anxiety disorder (GAD), separation anxiety disorder (SAD), or social phobia / social anxiety disorder. Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks. The primary aim of this study was to determine the safety and tolerability of GXR in youth with anxiety disorders, which involved the analysis of treatment - emergent adverse events (TEAEs), the emergence of suicidal ideation and behaviors, vital signs, and electrocardiographic / laboratory parameters. Exploratory efficacy measures included dimensional anxiety scales (Pediatric Anxiety Rating Scale [PARS] and Screen for Child Anxiety Related Emotional Disorders [SCARED]), as well as the Clinical Global Impression-Improvement (CGI-I) scale. As this was an exploratory study, no inferential statistical analyses were performed. GXR was safe and well tolerated. Treatment -related mean ± standard deviation changes in heart rate (GXR: 1.8 ± 12 beats per minute [bpm] decrease; placebo: 0.5 ± 11 bpm decrease), systolic blood pressure (GXR: 2.3 ± 11 mm Hg decrease; placebo: 1.7 ± 11 mm Hg decrease), or diastolic blood pressure (GXR: 1.3 ± 9 mm Hg decrease; placebo: 0.9 ± 7 mm Hg increase) were similar between treatment groups. TEAEs, including headache, somnolence / fatigue, abdominal pain, and dizziness, were consistent with the known safety profile of GXR. No differences were observed between treatment groups for PARS and SCARED scores, although at endpoint, a higher proportion of subjects receiving GXR versus placebo demonstrated CGI-I scores ≤2 (54.2% vs. 31.6%), as rated by the clinician investigator. GXR was well tolerated in pediatric subjects with GAD, SAD, and/or social anxiety disorder. ClinicalTrials.gov Identifier: NCT01470469.
28165762	0	16	Extended Release	T122	C1707968
28165762	17	27	Guanfacine	T109,T121	C0079466
28165762	31	40	Pediatric	T100	C0008059
28165762	41	58	Anxiety Disorders	T048	C0003469
28165762	62	67	Pilot	T062	C0031928
28165762	69	79	Randomized	T062,T170	C0206034
28165762	81	99	Placebo-Controlled	T062	C1706408
28165762	100	105	Trial	T062	C0008976
28165762	116	133	feasibility study	T062,T170	C0015730
28165762	134	144	evaluating	T058	C0220825
28165762	149	155	safety	T080	C0678800
28165762	157	169	tolerability	T062	C3274448
28165762	175	184	potential	T080	C3245505
28165762	185	204	anxiolytic efficacy	T039	C3179404
28165762	212	222	α2 agonist	T121	C2267005
28165762	223	233	guanfacine	T109,T121	C0079466
28165762	234	250	extended-release	T122	C1707968
28165762	252	255	GXR	T122	C1707968
28165762	260	268	children	T100	C0008059
28165762	273	284	adolescents	T100	C0205653
28165762	290	318	generalized anxiety disorder	T048	C0270549
28165762	320	323	GAD	T048	C0270549
28165762	326	353	separation anxiety disorder	T048	C0003477
28165762	355	358	SAD	T048	C0003477
28165762	364	377	social phobia	T048	C0031572
28165762	380	403	social anxiety disorder	T048	C4237417
28165762	405	410	Youth	T100	C0087178
28165762	411	415	aged	T032	C0001779
28165762	421	426	years	T079	C0439234
28165762	442	451	diagnosis	T033	C0011900
28165762	455	458	GAD	T048	C0270549
28165762	460	463	SAD	T048	C0003477
28165762	472	495	social anxiety disorder	T048	C4237417
28165762	501	513	treated with	T061	C0332293
28165762	523	528	dosed	T081	C0178602
28165762	529	532	GXR	T122	C1707968
28165762	541	546	daily	T079	C0332173
28165762	559	566	placebo	T122	C1696465
28165762	583	588	weeks	T079	C0439230
28165762	602	605	aim	T078	C1947946
28165762	614	619	study	T062	C2603343
28165762	641	647	safety	T080	C0678800
28165762	652	664	tolerability	T062	C3274448
28165762	668	671	GXR	T122	C1707968
28165762	675	680	youth	T100	C0087178
28165762	686	703	anxiety disorders	T048	C0003469
28165762	724	732	analysis	T062	C0936012
28165762	736	745	treatment	T061	C0087111
28165762	748	756	emergent	T078	C0750573
28165762	757	771	adverse events	T046	C0877248
28165762	772	779	(TEAEs)	T046	C0877248
28165762	785	794	emergence	T078	C0750573
28165762	798	815	suicidal ideation	T033	C0424000
28165762	820	829	behaviors	T053	C0004927
28165762	831	842	vital signs	T201	C0518766
28165762	848	868	electrocardiographic	T060	C0180580
28165762	871	881	laboratory	T073,T093	C0022877
28165762	882	892	parameters	T077	C0549193
28165762	906	914	efficacy	T080	C1280519
28165762	915	923	measures	T081	C0079809
28165762	945	959	anxiety scales	T170	C4050613
28165762	961	991	Pediatric Anxiety Rating Scale	T060,T170	C0870277
28165762	993	997	PARS	T060,T170	C0870277
28165762	1003	1055	Screen for Child Anxiety Related Emotional Disorders	T062	C0681906
28165762	1014	1019	Child	T100	C0008059
28165762	1020	1027	Anxiety	T033	C0003467
28165762	1036	1055	Emotional Disorders	T048	C0233459
28165762	1057	1063	SCARED	T062	C0681906
28165762	1082	1120	Clinical Global Impression-Improvement	T170	C3639708
28165762	1122	1127	CGI-I	T170	C3639708
28165762	1151	1168	exploratory study	T062	C1515369
28165762	1185	1205	statistical analyses	T062	C0871424
28165762	1222	1225	GXR	T122	C1707968
28165762	1244	1253	tolerated	T033	C0013220
28165762	1255	1264	Treatment	T061	C0087111
28165762	1274	1278	mean	T081	C0444504
28165762	1281	1299	standard deviation	T081	C0871420
28165762	1311	1321	heart rate	T201	C0018810
28165762	1323	1326	GXR	T122	C1707968
28165762	1337	1353	beats per minute	T081	C0439385
28165762	1355	1358	bpm	T081	C0439385
28165762	1360	1368	decrease	T081	C0547047
28165762	1370	1377	placebo	T122	C1696465
28165762	1388	1391	bpm	T081	C0439385
28165762	1392	1400	decrease	T081	C0547047
28165762	1403	1426	systolic blood pressure	T201	C0871470
28165762	1428	1431	GXR	T122	C1707968
28165762	1442	1447	mm Hg	T081	C0439475
28165762	1448	1456	decrease	T081	C0547047
28165762	1458	1465	placebo	T122	C1696465
28165762	1476	1481	mm Hg	T081	C0439475
28165762	1482	1490	decrease	T081	C0547047
28165762	1496	1520	diastolic blood pressure	T201	C0428883
28165762	1522	1525	GXR	T122	C1707968
28165762	1535	1540	mm Hg	T081	C0439475
28165762	1541	1549	decrease	T081	C0547047
28165762	1551	1558	placebo	T122	C1696465
28165762	1568	1573	mm Hg	T081	C0439475
28165762	1574	1582	increase	T169	C0442805
28165762	1605	1614	treatment	T061	C0087111
28165762	1615	1621	groups	T098	C1257890
28165762	1623	1628	TEAEs	T046	C0877248
28165762	1640	1648	headache	T184	C0018681
28165762	1650	1660	somnolence	T048	C2830004
28165762	1663	1670	fatigue	T184	C0015672
28165762	1672	1686	abdominal pain	T184	C0000737
28165762	1692	1701	dizziness	T184	C0012833
28165762	1734	1740	safety	T080	C0678800
28165762	1752	1755	GXR	T122	C1707968
28165762	1777	1785	observed	T169	C1441672
28165762	1794	1803	treatment	T061	C0087111
28165762	1804	1810	groups	T098	C1257890
28165762	1815	1819	PARS	T060,T170	C0870277
28165762	1824	1830	SCARED	T062	C0681906
28165762	1831	1837	scores	T081	C0449820
28165762	1851	1859	endpoint	T080	C2349179
28165762	1870	1880	proportion	T081	C1709707
28165762	1884	1892	subjects	T098	C0080105
28165762	1903	1906	GXR	T122	C1707968
28165762	1914	1921	placebo	T122	C1696465
28165762	1935	1940	CGI-I	T170	C3639708
28165762	1941	1947	scores	T081	C0449820
28165762	1986	2008	clinician investigator	T097	C0008961
28165762	2010	2013	GXR	T122	C1707968
28165762	2023	2032	tolerated	T033	C0013220
28165762	2036	2054	pediatric subjects	T098	C0080105
28165762	2060	2063	GAD	T048	C0270549
28165762	2065	2068	SAD	T048	C0003477
28165762	2077	2100	social anxiety disorder	T048	C4237417